#4-57E. Redefining Inflammatory Myopathies: Classification and Targeted Therapies (NEJM, 2026)

How do we tackle refractory muscle weakness and interstitial lung disease in idiopathic inflammatory myopathies? This comprehensive review reclassifies inflammatory myopathies into five distinct subtypes—inclusion-body myositis, immune-mediated necrotizing myopathies, antisynthetase syndrome, overlapping myositis, and dermatomyositis. It highlights the critical role of myositis-specific autoantibodies in diagnosing these subtypes and understanding their unique pathomechanisms. The most crucial clinical takeaway is the advent of personalized, targeted therapies tailored to specific autoantibody profiles, such as JAK inhibitors for dermatomyositis and CD19-targeted CAR-T cell therapy for severe antisynthetase syndrome. However, when critically appraising these advancements, clinicians must exercise caution, as the long-term safety and efficacy of these novel biologic and cellular therapies are yet to be fully established, pending the results of ongoing clinical trials. For practicing physicians, this article is highly relevant because it shifts the paradigm from broad immunosuppression to precise, individualized treatment strategies, ultimately empowering specialists to deliver more effective, targeted care for patients with these severe autoimmune conditions.

Citation: Allenbach Y, Benveniste O. Inflammatory Myopathies. New England Journal of Medicine. 2026. DOI: 10.1056/NEJMra2415426

Disclaimer: This audio summary is based on personal interpretation and does not guarantee the exact content of the original paper. Please refer to the original article for details.